A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world.
Amgen has created a number of websites to better serve you with specific questions.
At Amgen, we understand that we can only meet our ambitious 2027 Sustainability Goals with accurate performance measurement and fully transparent reporting. That’s why we follow guidelines from world-renowned organizations such as the European Union and the United Nations to take stock of our progress and keep pushing forward.
Our 2027 Sustainability Goals are built upon the foundations of innovation, efficiency, and renewable energy. By investing in new technologies, we can make our current operations more efficient, thereby reducing energy consumption and switching to alternatives where appropriate.
To determine our 2027 goals, Amgen consulted with academic and industry leaders to make the research, development, and manufacture of our medicines more sustainable.
To keep our Sustainability Goals on track, we employ a corporate governance program which is overseen by a Corporate Responsibility and Reputation Council. The Council ensures that all senior stakeholders are kept informed about our latest sustainability practices.
We report our findings to the Corporate Responsibility and Compliance Committee, which oversees all our activities in these key areas.
At Amgen, we maintain a policy of transparency to ensure every stakeholder can monitor our sustainability progress. We regularly share our success stories, highlighting our commitment to change, from award wins to new environmentally-friendly buildings.
We also run several comprehensive reports into our sustainability progress. The Responsibility Highlights Report examines our performance annually, assessing business ethics, governance, and the environment. Likewise, we publish yearly environmental performance data with key figures on energy consumption and compliance.
We take guidance from the following global organizations and non-profit initiatives to improve our reporting:
Our ‘sustainability by design’ ethos also looks at continually improving pharmaceutical manufacturing and packaging. This is guided by directives from the EU Registration, Evaluation and Authorization of Chemicals, the European Chemical Agency, and the European Federation of Pharmaceutical Industries and Associations.
Likewise, we regularly publish our findings for use in journals and industry presentations. By reporting on our moves towards more sustainable manufacturing and packaging, we can educate others and make our work public knowledge.
Our commitment to sustainability is only as strong as our workforce. This is why we hold regular stakeholder engagement sessions to gauge how our teams feel about Amgen Europe’s Corporate Responsibility.
These sessions cover key topics such as business ethics, product quality and safety, responsible sourcing, and environmental sustainability.
As part of our commitment to innovation, we use the latest data management systems for accurate sustainability reporting. For example, in our Netherlands division, we use a Smart and Integrated Facilities (SaIF) program to identify opportunities for improvement in energy, water, and overall operational efficiency.
Amgen currently has 17 manufacturing, research, and development facilities throughout North and South America, Asia, and Europe. To find out more about where we are and where we want to be, take a look at our resources below.